Vistin Pharma Valuation

Q: What is the Fair Price of 0RAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0RAM (NOK24.3) is trading below our estimate of [[fair value]] (NOK101.6)

Is 0RAM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RAM (NOK24.3) is trading below our estimate of fair value (NOK101.6)

Significantly Below Fair Value: 0RAM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RAM?

Key metric: As 0RAM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RAM. This is calculated by dividing 0RAM's market cap by their current earnings.
What is 0RAM's PE Ratio?
PE Ratio	16.9x
Earnings	NOK 61.37m
Market Cap	NOK 1.04b

0RAM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	10.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 0RAM's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RAM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	33.4x
ANCR Animalcare Group	32x	15.8%	UK£147.9m
EAH ECO Animal Health Group	74.1x	39.2%	UK£48.8m
HIK Hikma Pharmaceuticals	19x	12.7%	UK£4.3b
HVO hVIVO	8.5x	-15.2%	UK£148.0m
0RAM Vistin Pharma	16.9x	n/a	NOK 1.0b

Price-To-Earnings vs Peers: 0RAM is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (33.4x).

Price to Earnings Ratio vs Industry

How does 0RAM's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 0RAM is good value based on its Price-To-Earnings Ratio (16.9x) compared to the European Pharmaceuticals industry average (20x).

Price to Earnings Ratio vs Fair Ratio

What is 0RAM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RAM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0RAM's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

hVIVO

UK£148.0m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-1.1%

6.4%

Regeneron Pharmaceuticals

US$80.7b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$751.46

0.4%

-7.6%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.37

-1.4%

10.0%